Dr. Hertzel Gerstein

Division of Endocrinology and Metabolism

Hertzel C. Gerstein


Professor, Department of Medicine

Associate Member, Department of Clinical Epidemiology & Biostatistics

Director, Division of Endocrinology & Metabolism

Director, Diabetes Care and Research Program, McMaster University, Hamilton Health Sciences

Deputy Director, Population Health Research Instutite

Population Health Institute Chair in Diabetes Research

Education and Professional Standing

Dr. Hertzel C. Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Institute Chair in Diabetes Research. He is also Director of the Division of Endocrinology & Metabolism, Director of the Diabetes Care and Research Program and Deputy Director of the Population Health Research Institute. He has received several honors including the Canadian Diabetes Association’s Young Scientist Award (1999), Frederick G. Banting award (1999), and Charles H. Best award (2007).

Academic Interests

Dr. Gerstein has led the application of large simple outcome trials to people with diabetes globally, and developed the concept of dysglycemia as an important risk factor for many of the serious health outcomes that afflict people with an elevated glucose level regardless of diabetes status. He currently leads clinical trials and epidemiologic studies related to: a) the prevention and therapy of diabetes and its many consequences, and b) the role of dysglycemia and relative insulin insufficiency on the development of diabetes, cardiovascular disease, cognitive impairment and other chronic conditions. His research spans over 50 countries, and has been funded by the Canadian Institutes of Health Research, the National Institutes of Health, the Heart and Stroke Foundation, the Canadian Diabetes Association and Industry. Key studies in which he has played or continues to play a major leadership role include HOPE, MICRO HOPE, ACCORD, DREAM, EpiDREAM, ORIGIN, TIDE, ACE, CANVAS, ELIXA and REWIND. In addition to his research, he was the founding director of Diabetes Hamilton – a novel publicly available program that facilitated the ability of people with diabetes to best manage their disease.

Selected Publications

Dr. Gerstein has published more than 200 papers, editorials and commentaries, mainly on diabetes-related issues and co-edited the textbook Evidence-Based Diabetes Care. He is an Associate Editor for ACP Journal Club, and is on the editorial board of the Journal of Diabetes. He was the founding chair of the evidence-based committee for the CDA Evidence-based Clinical Practice Guidelines for the Management of Diabetes in Canada and developed their evidence-based approach.

  1. Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield JL, Ramachandran A, Riddle MC, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein HC. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia 2012;55:36-45. (PMID: 22038523)
  2. Anand SS, Tarnopolsky MA, Rashid S, Schulze KM, Desai D, Mente A, Rao S, Yusuf S, Gerstein HC, Sharma AM. Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). PLoS One 2011;6(7):e22112. Epub 2011 Jul 28.
  3. Sherifali D, Greb JL, Amirthavasar G, Hunt D, Haynes RB, Harper W, Holbrook A, Capes S, Goeree R, O'Reilly D, Pullenayegum E, Gerstein HC. Effect of Computer-Generated Tailored Feedback on Glycemic Control in People With Diabetes in the Community: A randomized controlled trial. Diabetes Care 2011;34:1794-1798. (PMID:21680723)
  4. Anand SS, Dagenais GR, Mohan V, Diaz R, Probstfield J, Freeman R, Shaw J, Lanas F, Avezum A, Budaj A, Jung H, Desai D, Bosch J, Yusuf S, Gerstein HC. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Card Prev Rehab (Epub May 6, 2011)
  5. Gerstein HC, Mohan V, Avezum A, et al. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators. Diabetologia. 2011;(3):487-95.
  6. Ismail-Beigi F, Craven TE, O'Connor PJ, Karl D, Calles-Escandon J, Hramiak I, Genuth S, Cushman WC, Gerstein HC, et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int. 2011 Dec 14. doi: 10.1038/ki.2011.415. [Epub ahead of print] (PMID 22166848)
  7. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011:969-977. (PMID 21958949)
  8. Anand SS, Tarnopolsky MA, Rashid S, Schulze KM, Desai D, Mente A, Rao S, Yusuf S, Gerstein HC, Sharma AM. Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the Molecular Study of Health and Risk in Ethnic Groups (mol- SHARE). PLoS One 2011;6(7):e22112. (PMID 21829446)
  9. Gerstein HC, Miller ME, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med; 2011:364(9):818-28. (PMID 21366473)
  10. Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation. 2011;123(3):342-8. (PMID: 21263007)
  11. Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care 2010;33:1578-1584 (PMID 20215456)
  12. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-74. (PMID 20228401)
  13. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17):1563-74. (PMID 20228404)
  14. Gerstein HC. Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers? JAMA 2010; 303(5):446-447
  15. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.  BMJ 2010; 8;340:b5444. PMCID PMC2803743
  16. Goyal A, Mehta SR, Díaz R, Gerstein HC, et al. Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction. Circulation 2009; 120(24):2429-37.
  17. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-2298. (PMID 19655124)
  18. Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24):2545-59. (PMID 18539917)